Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Icosavax, Inc. (ICVX : NSDQ)
 
 • Company Description   
Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company's virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc. is based in SEATTLE.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.41 Daily Weekly Monthly
20 Day Moving Average: 181,659 shares
Shares Outstanding: 39.73 (millions)
Market Capitalization: $294.40 (millions)
Beta:
52 Week High: $49.99
52 Week Low: $4.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.69% -16.38%
12 Week -56.51% -52.82%
Year To Date -67.61% -61.49%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1616 EASTLAKE AVE E SUITE 208
-
SEATTLE,WA 98102
USA
ph: 206-737-0085
fax: -
ir@icosavax.com http://icosavax.com
 
 • General Corporate Information   
Officers
Adam Simpson - Chief Executive Officer and Director
Mark McDade - Chairman
Thomas Russo - Chief Financial Officer
Elisha P. Gould - Director
Peter Kolchinsky - Director

Peer Information
Icosavax, Inc. (CORR.)
Icosavax, Inc. (RSPI)
Icosavax, Inc. (CGXP)
Icosavax, Inc. (BGEN)
Icosavax, Inc. (GTBP)
Icosavax, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45114M109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/12/22
Share - Related Items
Shares Outstanding: 39.73
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $294.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.08 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.04
Price/Cash Flow: -
Price / Sales: 46.12
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -30.43%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -71.88%
ROE
03/31/22 - -47.79
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -35.91
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - 31.02
09/30/21 - 36.67
Quick Ratio
03/31/22 - -
12/31/21 - 31.02
09/30/21 - 36.67
Operating Margin
03/31/22 - -1,326.23
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -1,326.23
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -858.38
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 7.13
09/30/21 - 7.42
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©